drugset / Trial / NCT00723411

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)

NCT00723411 ↗

Phase 3 Terminated 334 enrolled Diamyd Therapeutics AB
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.

Timeline

Start
2008-07
Primary completion
2011-05
Completion
2011-08

Outcome

Outcome not reported

Stopped: “The primary endpoint at 15 months was not met.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator rhGAD65 Vaccine 20 ug Subcutaneous